Reactions 1704, p58 - 2 Jun 2018 Hypertension: case report In a report of 43 patients, one patient [age and sex not stated] was described, who developed hypertension during treatment with axitinib for advanced renal cell carcinoma [dosage and route not stated]. The patient, who had advanced renal cell carcinoma, started receiving treatment with axitinib. Subsequently, the patient developed grade 3 hypertension [duration of treatment to reaction onset not stated]. The dose of axitinib was neither escalated nor reduced [outcome not stated]. Author comment: "We have assessed the efficacy and general tolerability of axitinib in a real world setting and audited our local dose escalation/reduction practice" "1 had a grade 3 hypertension" Parkar R, et al. Axitinib: An audit of dose adjustments, tolerability and efficacy in advanced renal cell carcinoma. Annals of Oncology 29 (Suppl. 3): iii30-iii31 (plus poster) abstr. 135P, Mar 2018. Available from: URL: https://doi.org/10.1093/ annonc/mdy047.082 [abstract] - United Kingdom 803323162 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera